

The Calcium Sensitizer Levosimendan Gives Superior Results to Dobutamine in Postoperative Low Cardiac Output Syndrome

Ricardo L. Levin, Marcela A. Degrange, Rafael Porcile, Flavio Salvagio, Norberto Blanco, Alejandro L. Botbol, Eduardo Tanus, and Carlos D. del Mazo

Servicios de Cirugía y Recuperación Cardiovascular, Hospital Universitario de la Universidad Abierta Interamericana y del Hospital Francés, Buenos Aires, Argentina

Introduction and objectives. The use of levosimendan to treat postoperative low cardiac output syndrome (LCOS) has been studied in only small patient series and in randomized trials focusing on hemodynamic variables. The objective of the present study was to assess the effectiveness of levosimendan, compared with dobutamine, as a treatment for postoperative LCOS.

Methods. Patients with LCOS were randomly assigned to receive either levosimendan (loading dose, 10 µg/kg, followed by 0.1 µg/kg per min for 24 h) or dobutamine (starting dose, 5 µg/kg per min). Hemodynamic and clinical parameters (including postoperative mortality and major complications), the need for the coadministration of another drug (such as an inotrope or a vasopressor) or for balloon counterpulsation, and length of stay in intensive care were all monitored.

Results. The study included 137 patients: 69 received levosimendan, while 68 were treated with dobutamine. Although both agents improved hemodynamic parameters, the effect of levosimendan was greater and occurred earlier than that of dobutamine. In addition, levosimendan use resulted in lower postoperative mortality (8.7% vs 25%; $P < .05$), a lower incidence of major postoperative complications, and less need for an additional inotropic drug (8.7% vs 36.8%; $P < .05$), a vasopressor (11.6% vs 30.9%; $P < .05$), or balloon counterpulsation (2.9% vs 14.7%; $P < 0.05$). The length of stay in intensive care was also less (66 vs 158 h; $P < .05$).

Conclusions. In this randomized study, levosimendan proved more effective than dobutamine. Postoperative morbidity and mortality were lower, fewer patients required either an additional inotropic drug, a vasopressor or intra-aortic balloon counterpulsation, and the length of stay in intensive care was shorter.

Key words: Levosimendan. Inotropic agents. Cardiac surgery. Low postoperative cardiac output.

Superioridad del sensibilizante al calcio levosimendán comparado con dobutamina en el síndrome de bajo gasto cardiaco postoperatorio

Introducción y objetivos. La consideración del levosimendán como tratamiento del síndrome de bajo gasto cardiaco (SBGC) postoperatorio se limita a series pequeñas o estudios aleatorizados sobre variables hemodinámicas. El objetivo del presente es evaluar, en una comparación con la dobutamina, la efectividad del levosimendán como tratamiento del SBGC postoperatorio.

Métodos. Se aleatorizó a los pacientes con SBGC a levosimendán (10 µg/kg en 1 h, seguido de 0,1 µg/kg/min por 24 h) o dobutamina (dosis inicial, 5 µg/kg/min). Se consideraron variables hemodinámicas y clínicas (mortalidad y complicaciones postoperatorias), necesidad de agregar otros fármacos (inotrópicos o vasopresores) o balón de contrapulsación, y tiempos de estancia en área intensiva.

Resultados. De los 137 pacientes incluidos, 69 recibieron levosimendán y 68, dobutamina. Ambos fármacos optimizaron variables hemodinámicas, si bien el efecto del levosimendán resultó superior y más precoz que dobutamina, además de reducir la mortalidad (el 8,7 frente al 25%; $p < 0,05$), las principales complicaciones postoperatorias y los requerimientos de un segundo inotrópico (el 8,7 frente al 36,8%; $p < 0,05$), vasopresor (el 11,6 frente al 30,9%; $p < 0,05$) y balón de contrapulsación (el 2,9 frente al 14,7%; $p < 0,05$). Asimismo, el tiempo de estancia en área de críticos resultó menor (66 frente a 158 h; $p < 0,05$).

Conclusiones. En una comparación aleatorizada con dobutamina, el levosimendán resultó superior, con reducción de la morbimortalidad postoperatoria, menor necesidad de agregar inotrópicos, vasopresores o balón y menos tiempo de estancia en área de cuidados intensivos.

Palabras clave: Levosimendán. Inotrópicos. Cirugía cardiaca. Bajo gasto postoperatorio.

SEE EDITORIAL ON PAGES 454-7

Correspondence: Dr. R. Levin,
1500 21st Avenue South, Nashville, 37212 Tennessee, United States
E-mail: rlevin@gmail.com; Ricardo.levin@vanderbilt.edu

Received October 3, 2007.
Accepted for publication January 22, 2008.

ABBREVIATIONS

CI: confidence interval
ECC: extracorporeal circulation
KATP: adenosine triphosphate-sensitive potassium channel
LCOS: low cardiac output syndrome
LS: levosimendan

INTRODUCTION

Low cardiac output syndrome (LCOS) is one of the most serious post-operative outcomes of cardiac surgery. It is associated with high morbi-mortality, increased use of resources, and a prolonged stay in a critical care unit.^{1,2}

The incidence of LCOS ranges between 3% and 20% in different studies, depending on factors such as the age of the population studied, the degree of pre-operative ventricular dysfunction, and the type of intervention. Treatment of LCOS usually includes the use of inotropic beta-adrenergic receptor agonists and/or phosphodiesterase III inhibitors, vasodilatory agents and, on occasions, intra-aortic balloon counterpulsation.³⁻⁵

Levosimendan (LS) is a new inotropic drug which belongs to the group of drugs known as calcium sensitizers. These act on the cardiovascular system through a double (at least) mechanism; firstly, through their interaction with the contractile proteins and remodeling which leads to enhancement of myocardial contractility and, secondly, through activation of the adenosine triphosphate-sensitive potassium channel (KATP). The end result includes arterial and venous vasodilation.^{6,7}

The action of LS has been widely studied in populations with complicated acute myocardial infarction and decompensated heart failure. Some of these studies have shown that the drug can reduce mortality. Less is known about its effects in the treatment of post-operative LCOS after cardiac surgery.⁸⁻¹⁰

The primary objective of the present study was to compare hospital mortality in patients with postoperative LCOS after coronary surgery with extracorporeal circulation (ECC) treated with LS or dobutamine. Secondary objectives were to assess the incidence of postoperative complications (morbidity), the need for additional inotropic agents or vasopressors, need for balloon counterpulsation, and time spent in intensive care.

METHODS

Population

Patients receiving coronary surgery with ECC in either of 2 teaching hospitals between December 1, 2003 and

December 1, 2006 were included consecutively and prospectively in the study.

Diagnosis of LCOS was established from hemodynamic data obtained using a Swan-Ganz catheter placed systematically during surgery after anesthetic induction. For the purposes of the present study, LCOS was defined as: pulmonary capillary pressure ≥ 16 mm Hg, cardiac index < 2.2 L/min/m², and mixed venous saturation $< 60\%$. Diagnosis of LCOS was performed in the first 6 hours after the intervention and after excluding or correcting temperature anomalies (hypothermia), pre-charge (hypovolemia), and the cardiac rhythm (bradycardia), cardiac tamponade, or postoperative ischemia. Patients meeting LCOS criteria were randomized using a computer generated algorithm to receive either LS at a loading dose of 10 $\mu\text{g}/\text{kg}$ for 1 h, followed by 0.1 $\mu\text{g}/\text{kg}/\text{min}$ for 24 h, or dobutamine 5 $\mu\text{g}/\text{kg}/\text{min}$ (if a favorable hemodynamic response was not observed, the dose was increased initially to 7.5, then to 10 and finally to 12.5 $\mu\text{g}/\text{kg}/\text{min}$ successively, at 15 min intervals). Dobutamine was chosen as it is the standard treatment for postoperative low output in the participating hospitals (and in Argentina in general) because of its hemodynamic effects, which are comparable to milrinone, but at a lower cost.

In cases where low cardiac output persisted, a second inotropic drug was added to the treatment regime (milrinone at a dose of 0.375 $\mu\text{g}/\text{kg}/\text{min}$). If LCOS remained unresolved, adrenalin was added as a third-line treatment at a dose of 1-10 $\mu\text{g}/\text{min}$. Finally, circulatory support was provided through balloon counterpulsation if required.¹¹

LS was administered via bolus in order to achieve a rapid hemodynamic effect. Administration was every 60 min (instead of the usual 10 min) after earlier experiences in our unit which showed it was possible to combine a rapid onset of action without producing the hypotension which frequently accompanies "conventional" administration. The maintenance dose chosen was within the usual range (0.05-0.2 $\mu\text{g}/\text{kg}/\text{min}$) and, again, it was chosen after a series of prior successful experiences both in a postoperative and preoperative context in patients with severe left ventricular dysfunction.¹²

Hemodynamic analyses were performed on diagnosis of LCOS (baseline, or time 0) and at time 1, or 1 hour after treatment initiation, and times 2, 3, 4, and 5 (6, 12, 24, and 48 h after diagnosis, respectively). Anesthetic and surgical techniques were similar. Fentanyl (10-20 $\mu\text{g}/\text{kg}$) was used with midazolam (0.03-0.05 mg/kg) to induce anesthesia. Intubation was facilitated using pancuronium. Sevoflurane, fentanyl, and propofol infusion (1-4 mg/kg/h) were employed as maintenance treatment. All procedures were performed using ECC and general myocardial ischemia through aortic clamping and electromechanical arrest with a cold, hyperpotasemic, blood cardioplegic solution administered intermittently.

Exclusion Criteria

Patients were excluded if they received emergency surgery, valvular, or combined techniques, surgery without ECC, low use of preoperative balloon counterpulsation or inotropic drugs, or if they had preoperative kidney failure (defined as glomerular filtration rate <59 mL/min).

Postoperative Complications (Morbidity)

The following complications were defined:

- Perioperative infarction: new pathologic Q waves (>0.04 s) in 2 contiguous derivations with an increase in creatine kinase (CK) >1000 U and MB fraction >10%
- Vasoplegia: arterial hypotension associated with reduced peripheral resistance of <800 din/s/cm⁵, with low filling pressures, normal or raised cardiac index, and need for vasopressors
- Kidney failure: increase in creatine of >50% associated or not with oliguria (diuresis <0.5 mL/kg/h)
- Prolonged ventilatory assistance: length of time on ventilator ≥24 h
- Stroke: a new focal neurological deficit or coma lasting over 48 h, after rejecting metabolic causes
- Systemic inflammatory response syndrome: presence of 2 or more of the following¹³: temperature >38 or <36°C; cardiac frequency >90 beats/min; respiratory frequency >20/min or PCO₂ <32 mm Hg; leukocytosis >12 000 or leukocytopenia <4000, or >10% of immature forms
- Sepsis: inflammatory response syndrome together with evidence of infection
- Pneumopathy: new pulmonary consolidation accompanied by a compatible clinical profile (fever, purulent expectoration) or documented infection site
- Adult respiratory distress: hypoxemia (ratio PaO₂/FiO₂ <150) which does not resolve with use of positive pressure or PEEP with a reduction in pulmonary distensibility and diffuse infiltrate
- Hospital mortality: death during hospital stay or in the first 30 days after the intervention

The following criteria were established for suspension of treatment: severe arterial hypotension, systolic blood pressure of <80 mm Hg with no response to volume expansion (2 charges of up to 500 mL each) or use of vasopressor drugs (phenylephrine up to 50 µg/min, noradrenalin up to 10 µg/min, vasopressin up to 0.04 U/min), development of myocardial ischemia (angina or elevated ST segment ST >2 mm), supraventricular tachycardia with a cardiac frequency of >130 beats/min, hemodynamic decompensation or ischemia, or sustained ventricular tachycardia without electrolytic alterations.

The study followed the principles of the Helsinki protocol and was approved by an institutional review board. Informed consent was obtained from the patient or a relative.

Statistical Analysis

Between group differences were analyzed using χ^2 or Fisher's exact test for categorical variables. The Student *t* test was used for continuous variables. Odds ratios and their corresponding 95% confidence intervals (CI) were used to analyze relationships between discrete variables. Numeric variables were expressed as means (standard deviation). Length of hospital stay was analyzed by comparing medians using the Mann-Whitney test. A *P* value less than .05 was considered significant.

RESULTS

Over the study period, a total of 1004 heart surgeries were performed and 137 patients (13.6%) met the criteria for postoperative LCOS. After informed consent was obtained from the patient or relative, 69 patients were randomized to treatment with LS and the remaining 68 patients were treated with dobutamine. Diagnosis of LCOS was made in all cases within 3 hours of the intervention (2.3 h for patients treated with LS and 2.2 h for those treated with dobutamine). Treatment was initiated approximately 30 min after diagnosis in all patients (21.4 min in the LS group and 19.8 min in the dobutamine group).

The 2 study groups were similar in terms of their overall characteristics, preoperative medication, and the main variables describing the intervention (Tables 1 and 2).

Figures 1-5 show the principle hemodynamic findings. Both agents had beneficial effects on hemodynamic parameters, though the favorable effect was more marked and of faster onset in patients treated with LS.

The mean dose of dobutamine was 9.2 (8.3) (range, 5-11) µg/kg/min in patients who had not been previously treated with beta-blockers and 10.5 (8-13) µg/kg/min in patients who had received beta-blockers previously.

A total of 23 patients (16.8%) died during the study period, 6 (8.7%) in the LS group and 17 (25%) in the dobutamine group (*P*=.01; OR=0.29; 95% CI, 0.09-0.85). None of the deaths occurred within 48 h of initiating treatment; the first death occurred 99 h after starting treatment in the LS group and 96 h after initiating treatment in the dobutamine group (the difference was not significant).

Causes of death in the dobutamine group were: cardiac, 10 patients (8 cases of refractory low output and 2 patients with refractory ventricular arrhythmia), neurological in 2 patients, and multi-organ failure in 5. In the LS group, causes of death were: cardiac in 2 patients, neurological in 1 patient, and multi-organ failure in the remaining 3 patients. The difference in cardiac-based mortality was statistically significant (*P*=.014; OR=0.17; 95% CI, 0.03-0.89); differences for the other causes of death were not statistically significant.

Table 3 shows the principal postoperative complications. There were fewer complications in the LS group. The

TABLE 1. General and Surgery–Related Characteristics of the Study Population^a

Characteristic	Levosimendan (n=69)	Dobutamine (n=68)
Women, n (%)	26 (37.7)	27 (39.7)
Age, mean, y	62.4	61.7
Diabetes, n (%)	21 (30.4)	19 (27.9)
High blood pressure, n (%)	36 (52.2)	35 (51.5)
Prior infarction, n (%)	12 (17.4)	12 (17.6)
Prior surgery, n (%)	15 (21.7)	14 (20.6)
Prior angioplasty, n (%)	16 (23.2)	14 (20.6)
Preoperative EF, mean (SD), %	36.62 (4.36)	38.22 (5.24)
Estimated glomerular filtration rate, mean (SD), mL/min/1.73	84.32 (3.27)	85.52 (4.15)
Number of bridges	3.4	3.4
Time with ECC, mean (SD), min	82.4 (15.3)	80.9 (17.2)
Time with aortic clamp, mean (SD), min	64.6 (14.2)	63.2 (12.8)

^aECC indicates extracorporeal circulation; EF, ejection fraction; SD, standard deviation.

In all cases (Fisher’s test for categorical variables and Student *t* test for continuous variables), differences were not statistically significant.

TABLE 2.

Medication	Levosimendan (n=69), n (%)	Dobutamine (n=68), n (%)
Aspirin	65 (94.2)	66 (97.1)
Clopidogrel	9 (13)	7 (10.3)
ACE inhibitors	38 (55.1)	33 (48.5)
Beta-blockers	61 (88.4)	45 (85.3)
Calcium antagonists	18 (26.1)	24 (23.5)
Nitrites	42 (60.9)	43 (63.2)
Amiodarone	7 (10.1)	6 (8.8)
Digoxin	7 (10.1)	5 (7.3)
Statins	38 (55.1)	36 (52.9)
Diuretics	14 (20.3)	14 (20.6)
Anticoagulants	8 (11.6)	5 (7.3)

^aACE indicates angiotensin converting enzyme.

In all cases, differences were not statistically significant (Fisher’s test for categorical variables).

difference was statistically significant for perioperative infarction, systemic inflammatory response syndrome, vasoplegia, sepsis, kidney failure, and ventricular arrhythmia. Prolonged ventilatory assistance was less frequently required in the LS group. It was not necessary to suspend the treatment protocol in any of the 137 patients treated, though volume expansion was required in 20 LS patients and in 51 patients in the dobutamine group (29% vs 75%; *P*=.0001; OR=0.25; 95% CI, 0.12-0.55).

Additional inotropic agents were less frequently required in the LS group. A second inotropic agent was required in 6 patients in the LS group (8.7%) compared to 25 (36.8%) patients in the dobutamine group (*P*<.0001; OR=0.16; 95% CI, 0.05-0.47), while a third inotropic was required in 2 patients (2.9%) in the LS group and in 10 patients (14.7%) in the dobutamine group (*P*=.014; OR=0.17; 95% CI, 0.03-0.89). Two patients (2.9%) required balloon treatment in the LS group compared to




Figure 1. Comparative evolution of cardiac index during treatment. *Between group difference statistically significant (expressed as mean [standard deviation] and calculated using the Student *t* test).




Figure 2. Comparative evolution of mixed venous saturation during treatment. *Between group difference statistically significant (expressed as mean [standard deviation] and calculated using the Student *t* test).




Figure 3. Comparative evolution of pulmonary capillary pressure during treatment. *Between group difference statistically significant (expressed as mean [standard deviation] and calculated using the Student *t* test).




Figure 4. Comparative evolution of arterial blood pressure during treatment. Differences were not statistically significant.




Figure 5. Comparative evolution of cardiac frequency during treatment. Differences were not statistically significant.

10 (14.7%) in the dobutamine group ($P=.014$; $OR=0.17$; 95% CI, 0.03-0.89).

Eight patients (17.6%) in the LS group required vasopressors compared to 21 (25%) in the dobutamine group ($P=.005$; $OR=0.29$; 95% CI, 0.11-0.75).

Mean (median) length of stay in intensive care was 88 h (66-156 h for the first and third quartiles, respectively). Length of stay was lower in the LS group: 66 h (58-74) compared to 158 h (106-182) ($P<.05$).

The postoperative ejection fraction, which was assessed before discharge from hospital, was 54.23% (4.65%) in the LS group compared to 45.64% (5.21%) in the dobutamine group. A second evaluation 90 days after the intervention gave values of 57.65% (3.37%) in patients treated with LS and 53.46% (4.20%) in patients who received dobutamine.

DISCUSSION

This is one of the first randomized studies to show a decrease in hospital mortality, smaller number of complications, reduced length of stay in critical care units, and smaller use of additional inotropic or vasopressor agents and balloon counterpulsation in patients with postoperative LCOS treated with LS or dobutamine. Although hemodynamic parameters improved with both drugs, the improvement was larger and onset of action was quicker in patients treated with LS. The larger gains with LS can be seen in parameters which evaluate systolic function, such as the cardiac index (50% increase in the first hour of treatment), as well as in variables used to measure tissular metabolic condition, such as mixed venous

TABLE 3. Principal Postoperative Complications

Complication	Levosimendan (n=69), No. (%)	Dobutamine (n=68), No. (%)	P
Perioperative infarction	1 (1.4)	8 (11.8)	<.05
Vasoplegia	1 (1.4)	9 (13.2)	<.05
Acute kidney failure	5 (7.2)	21 (30.9)	<.05
Need for dialysis	2 (2.9)	8 (11.8)	NS
Atrial fibrillation	15 (21.7)	27 (39.7)	NS
Ventricular arrhythmia	3 (4.3)	12 (17.6)	<.05
Dyspnea	1 (1.4)	4 (5.8)	NS
Pneumonia	4 (5.8)	10 (14.7)	NS
Inflammatory response syndrome	4 (5.8)	15 (22.1)	<.05
Sepsis	1 (1.4)	9 (13.2)	<.05
Prolonged ventilatory assistance	6 (8.7)	22 (32.3)	<.05
Stroke	2 (2.9)	6 (8.8)	NS
Mortality	6 (8.7)	17 (25)	<.05

saturation (which increased 29.6% in the same period). Added to this was the 35.5% decrease in pulmonary capillary pressure values, again within the first hour of treatment.

These observations support our initial expectations. Under experimental conditions, LS has been shown to be associated with greater contraction force in samples of isolated heart tissue, both in comparison to beta-adrenergic receptor agonists as well as to phosphodiesterase III inhibitors. The quicker onset of action has also been noted. A quicker reversal of LCOS, as with any unfavorable hemodynamic profile, is important for prognosis, as has been shown recently with sepsis. The lower number of postoperative complications can be explained by the quicker reversal, which no doubt also played a role in the lower rate of observed mortality.¹⁴⁻¹⁷

The specific, and in some cases differential, actions of LS in comparison to other inotropic medicines provide the rest of the interpretation. LS has been shown to have a dual action: it acts first on troponin C, which it sensitizes to calcium, thereby increasing contractility without increasing cyclical adenosine monophosphate (AMPc) nor the intracellular quantity of calcium nor consumption of myocardial oxygen. These effects have been associated in conventional inotropics with cardio-toxicity, progression of heart failure, development of ischemia, proarrhythmic effect, major apoptosis, and increased mortality.¹⁸⁻²⁰

Additionally, LS, through the activation of the KATP, produces vasodilatory effects (arterial, coronary, and venous), decreased pre-load and post-load, and coronary, pulmonary, and mammary vasodilation. The same mechanism of action suggests both anti-ischemic and cardio-protective effects for LS. The agent itself would generate pharmacological preconditioning which favors the recovery of stunned myocardium. This would be particularly beneficial in situations of ischemia-reperfusion which are frequent in postoperative cardiac surgery with ECC, where loss of calcium sensitivity by the contractile apparatus is one of the mechanisms present. LS, in contrast to other inotropic agents, increases reduced sensitivity. Beta-adrenergic receptor agonists, on the other hand, have been shown in experiments to increase that desensitization. Several studies have also indicated a reduction in myocardial damage as shown by smaller increases in troponin. In the present study, we consider the lower incidence of perioperative infarction to likely be an expression of the aforementioned cardio-protective effect.²¹⁻²⁴

On the other hand, the fact that increased sensitization is limited to the systole means that LS does not alter the diastolic properties or have a positive lusotropic effect.

Another of the drug's notable characteristics is the reduction in the values of inflammatory parameters, such as cytokines, a fact which has not been evaluated in postoperative patients, although our lower incidence of

inflammatory response syndrome and vasoplegia could be evidence of the aforementioned anti-inflammatory effect.^{18,25}

There have been relatively few reports of the use of LS in postoperative LCOS and most have not been from randomized trials. Ploecl, Labriola, and Tokuda have reported on 3 clinical series, though the number of patients included was low (12, 11, and 9 patients, respectively). Nevertheless, the 3 reports coincided in showing a significant improvement in hemodynamic parameters with LS.²⁶⁻²⁸

Álvarez et al evaluated a total of 41 patients with postoperative LCOS in a randomized study which, like those mentioned above, compared LS and dobutamine on hemodynamic parameters. They concluded that both drugs led to an improvement on those parameters, though LS significantly reduced systemic valvular and pulmonary resistance with a larger decrease in systemic arterial, pulmonary, central venous, and pulmonary capillary pressure.²⁹

In another randomized study, Tasouli et al compared 45 patients with LCOS treated with LS at 2 different time points. The patients had been treated with inotropics and/or balloon counterpulsation. The study showed better results in those who were treated earlier, with a shorter time on inotropic support, a lower incidence of sepsis, and a shorter length of stay in intensive care units and in hospital in general.³⁰

It should be borne in mind that the LS doses used in these studies differed from those used here. Our choice of a lower loading dose administered over a longer period was based on prior experience with the drug which had showed that this approach was associated with fewer adverse events. In particular, we had found that this approach led to a lower incidence of severe arterial hypotension (only 11.6% of patients required vasopressors), and without the need to suspend treatment in any case.

The increase in the postoperative ejection fraction was reasonable and as expected when taking into account that, although it was low in the preoperative phase, the majority of dysfunctions were ischemic in nature (17% of patients with a previous infarction). Likewise, patients in the LS group recovered function more quickly.

Study Limitations

In the first place, although this is one of the largest series of LCOS patients treated with LS followed to date, the numbers are still low. Nevertheless, all of the patients randomized were treated effectively and, in this sense, the low number included could have been beneficial. Second, we did not use a double blind design. A double blind trial would be very useful in helping to confirm the results presented here. The fact that a double blind design was not used could have influenced our results, although

the 2 study groups were comparable and those responsible for data collection and analysis were unaware of patient assignment. The dose of LS used could also be questioned, although this tends to vary across studies, as mentioned above.

Despite these considerations, the favorable results nevertheless provide a stimulus for further research on the use of LS in this context. Such research would be useful in confirming the results of the present study.

CONCLUSIONS

In this randomized comparison of dobutamine and LS in patients with postoperative LCOS, LS was associated with greater improvement on hemodynamic parameters and a faster onset of action, as well as with lower mortality and complication rates, lower use of additional inotropic and vasopressor drugs, less need for balloon counterpulsation, and shorter length of stay in intensive care.

These findings suggest that LS is an effective treatment for this particular clinical condition. Studies with larger numbers of patients will help to determine the value of the present findings.

REFERENCES

- Kirklin J, Barrat-Byes B. Postoperative care. En: Kirklin J. Cardiac surgery. 2.^a ed. New York: Churchill Livingstone; 1993. p. 195-247.
- Rao V, Ivanov J, Weisel RD, Ikonomidis JS, Christakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. *J Thorac Cardiovasc Surg.* 1996;112:38-51.
- Henquin RP, Bozovich GE, Aranda G, Ciruzzi MI, Nadilnic BM, Fabrikant F, et al. CONAREC III. Predictores independientes de bajo gasto cardiaco en el preoperatorio de cirugía de revascularización miocárdica. *Rev Argent Cardiol.* 1996;64:179-86.
- Doyle AR, Dhir AK, Moors AH, Latimer RD. Treatment of perioperative low cardiac output syndrome. *Ann Thorac Surg.* 1995;59:S3-11.
- Levy J, Bailey J, Deeb G. Intravenous milrinone in cardiac surgery. *Ann Thorac Surg.* 2002;73:325-30.
- Figgitt DP, Gillies PS, Goa JL. Levosimendan. *Drugs.* 2001;61:613-27.
- Papp Z, Csapo K, Pollesello P, Haikala H, Edes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. *Cardiovasc Drug Rev.* 2005;23:71-93.
- Follath F, Cleland JGF, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double blind trial. *Lancet.* 2000;360:196-202.
- Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan in patients with left ventricular failure due to an acute myocardial infarction (RUSSLAN study). *Eur Heart J.* 2002;23:1422-32.
- Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Thakkar R, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure. The SURVIVE Randomized Trial. *JAMA.* 2007;297:1883-91.
- Feneck RO, Sherry KM, Withington PS, Oduro-Dominah A, and the European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. *J Cardiothorac Vasc Anesth.* 2001;15:306-15.
- Levin RL, Degrange MA, Porcile R, Salvagio F, Blanco N, Botbol LA. The preoperative utilization of levosimendan (preoperative optimization) reduced mortality and low output syndrome after cardiac surgery in patients with low ejection fraction (EF<25%). *Circulation.* 2007;116:II-682.
- American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med.* 1992;20:864-74.
- Usta C, Puddu P, Papalia U, de Santis V, Vitale D, Tritapepe L, et al. Comparison of the inotropic effects of levosimendan, rolipram, and dobutamine on human atrial trabeculae. *J Cardiovasc Pharmacol.* 2004;44:622-5.
- Braun JP, Schneider M, Kastrup M, Liu J. Treatment of acute heart failure in an infant after cardiac surgery using Levosimendan. *Eur J Cardiothorac Surg.* 2004;26:228-30.
- Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med.* 2001;345:1368-77.
- Rivers E, McIntyre L, Morro DC, Rivers KK. Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. *CMAJ.* 2005;173:1054-65.
- Raja SG, Rayen BS. Levosimendan in cardiac surgery: Current best available evidence. *Ann Thorac Surg.* 2006;81:1536-46.
- Nijhawan N, Nicolosi AC, Montgomery T, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective randomized placebo-controlled trial. *J Cardiovasc Pharmacol.* 1999;34:219-28.
- García-Gonzalez MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, Abreu-Gonzalez P, Bethencourt Muñoz M. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. *Eur J Heart Fail.* 2006;8:723-8.
- Kopustinskiene DM, Pollesello P, Saris NEL. Potassium-specific effects of levosimendan on heart mitochondria. *Biochem Pharmacol.* 2004;68:807-12.
- García-Gonzales MJ, Domínguez-Rodríguez A. Efectos del levosimendan en el tratamiento del aturdimiento miocárdico y del síndrome de bajo gasto después de cirugía cardiaca. *Rev Esp Cardiol.* 2006;59:851-2.
- de Hert SG, Lorsomradee S, Cromheecke S, van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. *Anesth Analg.* 2007;104:766-73.
- Tritapepe L, de Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, et al. Preconditioning effects of Levosimendan in coronary artery bypass grafting-a pilot study. *Br J Anaesth.* 2006;96:694-700.
- Pagel PS. Levosimendan in cardiac surgery: A unique drug for the treatment of perioperative left ventricular dysfunction or just another inodilator searching for a clinical application? *Anesth Analg.* 2007;104:759-61.
- Plochl W, Rajek A. The use of the novel calcium sensitizer levosimendan in critically ill patients. *Anaesth Intensive Care.* 2004;32:471-5.
- Labriola C, Siro-Brigiani M, Carrata F, Santangelo E, Amantea B. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. *Int J Clin Pharmacol Ther.* 2004;42:204-11.
- Tokuda Y, Grant PW, Wolfenden HD, Manganas C, Lyon WJ, Murata JSK. Levosimendan for patients with impaired left ventricular function undergoing cardiac surgery. *Interact CardioVasc Thorac Surg.* 2006;5:322-6.
- Álvarez J, Bouzada M, Fernández AL, Caruezo V, Taboada M, Rodríguez J, et al. Comparación de los efectos hemodinámicos del

- levosimendán con la dobutamina en pacientes con bajo gasto después de cirugía cardíaca. *Rev Esp Cardiol*. 2006;59:338-45.
30. Tasouli A, Papadopoulos K, Antoniou T, Kriaras I, Stavridis G, Degiannis D, et al. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use. *Eur J Cardiothorac Surg*. 2007;32:629-33.